Toralizumab (IDEC-131) is a humanized monoclonal antibody (mAb) against CD40L (CD154) comprised of human gamma 1 heavy chains and human kappa light chains. Toralizumab binds specifically to human CD40L on T cells, thereby preventing CD40 signaling. Toralizumab, a immunosuppressive agent, has the potential for active systemic lupus erythematosus (SLE) research
Form:Liquid
IC50& Target:CD40L
规格
别名
托拉珠单抗
英文名称
Toralizumab
生化机理
托瑞珠单抗(IDEC-131)是一种针对CD40L(CD154)的人源化单克隆抗体(mAb),CD40L由人类γ1重链和人类卡帕轻链组成。Toralizumab 能与 T 细胞上的人类 CD40L 特异性结合,从而阻止 CD40 信号传导。托拉瑞